Treatment patterns, health resource consumption, and costs of patients with migraine in an Italian real-world setting. (1st December 2020)

• Record Type: Journal Article
• Authors: Perrone, Valentina; Veronesi, Chiara; Giacomini, Elisa; Andretta, Margherita; Dell'Orco, Stefania; De Sarro, Giovambattista; Lena, Fabio; Menti, Anna Michela; Naclerio, Mariantonietta; Ritrovato, Daniela; Degli Esposti, Luca
• Is Part Of: Current medical research and opinion. Volume 36:Number 12(2020)
• Page Start: 1991
• Page End: 1998
• Publication Date: 2020-12-01
• Subjects: Drug-utilization -- migraine prophylaxis -- real-world study -- therapeutic pathway; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2020.1835850
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: This study aimed to describe the demographic and clinical characteristics of migraineurs prescribed ≥1 migraine prophylactic therapy, and to analyze their therapeutic pathways, healthcare resource consumption, and related costs. Methods: This retrospective analysis was based on administrative databases from two regions and three local health units in Italy. Adult patients with ≥1 discharge diagnosis for migraine or ≥1 prescription for migraine-specific drugs, or ≥1 emergency room visit for migraine from 1 January 2010 to 31 December 2016 were included if they had received ≥1 migraine prophylactic therapy between 1 January 2011 and 31 December 2015 (enrollment period). The first date of the last migraine prophylactic treatment was considered as the index date (ID). Patients were characterized 1-year prior ID and followed-up for 1 year afterwards. Results: Of the 166, 362 identified migraineurs, 32, 794 (mean age: 45.9 ± 13.9 years, 19.2% male) who received migraine prophylaxis were included in the analysis. At ID, 31, 629 patients had received 1 prophylactic treatment with antidepressants (51.2%), neuromodulators (28.1%), beta blockers (12.4%), other migraine preparations (7.8%), and botulinum toxin A (0.5%). Focusing on patients with one prophylactic treatment at ID, 85.4% did not have any previous therapeutic failures whereas 14.6% had ≥1 previous failure. During follow-up, 5% of patients made a therapeutic switch after a mean period of 103.4 ± 97.9 days. Total mean annual cost for patients receiving migraine prophylaxis was 1193.64€ during characterization and 1303.86€ during follow-up periods. Conclusion: This real-world study gave insights on the characterization of migraineurs and patterns of prophylaxis utilization in Italian clinical settings, showing an underuse of prophylactic agents.